Price
No data yet.
Social Signal Score
Revenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Fred Aslan
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 115
- Beta
- 2.18
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 14.51
Financials
Revenue
$0.00-100.0%Net Income
$-25.00MEBITDA
$-23.65MFree Cash Flow
$-41.96MEPS (diluted)
$-0.63Shares Outstanding (diluted)
39.41M+124.2%Operating Expenses
$26.89MCash & Debt
$349.39MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-83.86M | $-3.43 |
| 2024 | $251.0K | $-58.49M | $-5.20 |
| 2023 | $33.49M | $-27.70M | $-1.19 |
| 2022 | $4.93M | $-58.39M | $-3.32 |
| 2021 | $2.00M | $-71.83M | $-4.08 |
| 2020 | $0.00 | $-17.99M | $-1.02 |
Valuation
ARTVhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80Social Signal Score
Mentions (1)
- Newsglobenewswire.com·1d ago·Negative
…tiva Biotherapeutics to Participate in Upcoming Investor Conferences in September SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that management will participate at the following investor conferences: 2026 Cantor Global Healthcare Conference – live fireside chat on …
View source ↗
Earnings
Wed, Nov 11(in 2 months)
Consensus estimate $-0.54 per share
Typical surprise -0.8% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.63 vs $-0.63miss
- Fri, May 8$-0.95 vs $-0.88miss
- Tue, Mar 10$-0.84 vs $-0.87beat
- Wed, Nov 12$-0.88 vs $-0.92beat
- Wed, Aug 6$-0.87 vs $-0.84miss
- Thu, May 8$-0.83 vs $-0.68miss
Estimates and results for ARTV via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ARTV officers and directors.
- Bought
- $109.2m
- Sold
- $845k
23 trades
11 trades
- Banerjee Subhashissold
- Banerjee Subhashissold
- Ra Capital Management, L.p.bought
- Ra Capital Management, L.p.bought
- Ra Capital Management, L.p.bought
- Ra Capital Management, L.p.bought
- Ra Capital Management, L.p.bought
- Ra Capital Management, L.p.bought
66 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.